The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in ...
Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential ...
Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non ...
The Company remains on track to complete 12-month visits by early Q2 2027. Envoy Medical has submitted two of the four ...
Favorable interim safety and tolerability profile observed across single and multiple ascending dose cohorts in healthy ...
In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44 In CD, ...
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today ...
Designation follows recent IND activation and builds on Orphan Drug Designation granted in 2025. NEW YORK, Oct. 20, 2026 ...
Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based ...
AbbVie (NYSE: ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming ...
Gilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ...
Autologous Cutaneous Multicellular Units in Non-Healing Wagner 1 Diabetic Foot Ulcers: Results of the Phase 3 COVER DFUS II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results